Publications by authors named "Claudio Dansky Ullmann"

Claim this Profile
R
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
Taofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Tibor Csoszi, Gyula Ostoros, Claudio Dansky Ullmann

J Thorac Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.
Xiaofei Zhou, Sandeepraj Pusalkar, Swapan K Chowdhury, Shawn Searle, Yuexian Li, Claudio Dansky Ullmann

Invest New Drugs· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
Owen A O'Connor, Muhit Özcan, Eric D Jacobsen, Josep M Roncero, Judith Trotman, Claudio Dansky Ullmann

J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Gerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, Razelle Kurzrock, Devalingam Mahalingam, Claudio Dansky Ullmann

Drugs R D· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Gerald S Falchook, Karthik Venkatakrishnan, John Sarantopoulos, Razelle Kurzrock, Alain C Mita, Claudio Dansky Ullmann

Int J Clin Pharmacol Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
Bohuslav Melichar, Antoine Adenis, A Craig Lockhart, Jaafar Bennouna, E Claire Dees, Claudio Dansky Ullmann

Lancet Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival.
Helen M Parsons, Linda C Harlan, Jennifer L Stevens, Claudio Dansky Ullmann

Cancer J· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.
Shakun M Malik, Richard Pazdur, Jeffrey S Abrams, Mark A Socinski, William T Sause, Claudio Dansky Ullmann

J Thorac Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia.
David J Adelstein, John A Ridge, David M Brizel, F Christopher Holsinger, Bruce H Haughey, Claudio Dansky Ullmann

Head Neck· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based study of therapy and survival for patients with head and neck cancer treated in the community.
Claudio Dansky Ullmann, Linda C Harlan, Vickie L Shavers, Jennifer L Stevens

Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting embryonic signaling pathways in cancer therapy.
Pamela Jo Harris, Giovanna Speranza, Claudio Dansky Ullmann

Expert Opin Ther Targets· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".
Paolo A Ascierto, Eleonora De Maio, Stefano Bertuzzi, Giuseppe Palmieri, Ruth Halaban, Claudio Dansky Ullmann

J Transl Med· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer stem cells and targeting embryonic signaling pathways.
Claudio Dansky Ullmann

J Thorac Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C.
David J Adelstein, John A Ridge, Maura L Gillison, Anil K Chaturvedi, Gypsyamber D'Souza, Claudio Dansky Ullmann

Head Neck· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Richard A Messmann, Claudio Dansky Ullmann, Tyler Lahusen, Audrey Kalehua, Jason Wasfy

Clin Cancer Res· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis